AbbVie Gives Up On One Of Alector’s Alzheimer’s Candidates But Plenty More In Pipeline
Partners Still Working On Another Drug
The major has terminated its deal with Alector for a SIGLEC-3 targeting Alzheimer’s candidate but is forging ahead with another novel drug covered by the firms’ collaboration in the challenging condition.
You may also be interested in...
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.